###### Strengths and limitations of this study

-   The strength of this study is that this is the first collaboration study in the Asia-Pacific region and will include more than 1000 patients to identify the clinical characteristics of patients with autosomal dominant polycystic kidney disease (ADPKD) with rapid progression.

-   Detailed clinical follow-up data of at least 2 years will be collected, including clinical manifestations, laboratory results, renal radiological findings and Predicting Renal Outcomes in autosomal dominant Polycystic Kidney Disease (PRO-PKD) scores, and are expected to provide knowledge on the incidence of renal and extrarenal complications, diagnostic pattern, and the effects of ethnicity and water intake on disease progression.

-   Due to the nature of a retrospective observational study, renal function and kidney volume measurement methods could not be unified, and follow-up duration and interval would differ among patients.

-   We anticipate more collaboration studies among Asia-Pacific countries will be derived from our study, which can benefit the Asia-Pacific ADPKD population.

Introduction {#s1}
============

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease in all races.[@R1] About 50% of patients with ADPKD progress to end-stage renal disease (ESRD) in their fifth decade, and ADPKD is currently the fourth main cause of ESRD.[@R2] In addition to renal progression, various renal and extrarenal symptoms and complications occur in patients with ADPKD during their life. ADPKD is a heterogeneous set of diseases caused by a mutation in either two genes, *PKD1* and *PKD2*. Patients with *PKD2* mutation show a milder clinical course compared with those with *PKD1* mutation.[@R3] However, even in the same family, with the same germline mutation in *PKD1/PKD2* gene, manifestations and severity of disease differ from person to person.[@R2] These differences in disease manifestations and progression might be due to various environmental factors, in addition to genetic factors.[@R4] Therefore, identifying patients who will develop severe disease is important in the clinical management of ADPKD. Moreover, since the approval of vasopressin V2 receptor antagonists by the US Food and Drug Administration as the first medication to slow ADPKD progression, identifying the 'rapid progressor' has been a crucial step in deciding which patients will benefit most from the treatment.[@R5]

However, there have been only a few studies that characterised the nature of the disease and that analysed the progression of ADPKD in the Asia-Pacific population ([table 1](#T1){ref-type="table"}). A few unique characteristics of the Asian ADPKD population have been noted in previous studies. About 50%--80% of genetic mutations in the *PKD1* or *PKD2* gene of the Asian population were novel compared with a previous genetic mutation database based on the Western population.[@R6] In addition, differences in genetic background, race, climate, culture and lifestyle of the Asian population can also affect disease progression differently. Limited data suggest the possibility of faster renal progression in Asian patients with chronic kidney disease (CKD) compared with the Western population.[@R9] However, previous studies on Asian ADPKD populations were conducted in a single country, which under-represented the whole Asian ADPKD population.[@R12] Moreover, to date, studies that identified patients with ADPKD with rapid progression were mostly conducted in the Western population.[@R5] Therefore, a larger, multicentre study is needed to determine the clinical characteristics and to define the risk factors for rapid progression of ADPKD in Asian patients.

###### 

Summary of studies on the clinical characteristics or renal progression of Asian patients with ADPKD

  Country       Subject of the study                                                                                                                                                                                             Patients (n)   Study type                         Year of publication   Reference
  ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ---------------------------------- --------------------- -----------
  Australia     Genotype--phenotype correlation                                                                                                                                                                                  285            Cross-sectional study              1992                  [@R12]
  China         Clinical manifestation                                                                                                                                                                                           205            Cross-sectional study              1995                  [@R13]
  China         Clinical characteristics and disease progression                                                                                                                                                                 541            Prospective cohort study           2014                  [@R14]
  China         Genotype--phenotype correlation                                                                                                                                                                                  148            Cross-sectional study              2016                  [@R15]
  China         Clinical features of inpatients with ADPKD                                                                                                                                                                       168            Retrospective study                2018                  [@R16]
  Iraq          Clinical manifestation                                                                                                                                                                                           30             Cross-sectional study              2011                  [@R17]
  Japan         Renal progression                                                                                                                                                                                                255            Retrospective study                2012                  [@R18]
  Japan         Genotype and renal progression                                                                                                                                                                                   112            Retrospective study                2015                  [@R19]
  Japan         Renal progression and effect of tolvaptan in a Japanese subset of patients from Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial   177            Subgroup study of clinical trial   2015                  [@R20]
  Japan         Clinical characteristics according to Mayo classification                                                                                                                                                        296            Retrospective study                2019                  [@R21]
  Pakistan      Clinical presentation                                                                                                                                                                                            56             Cross-sectional study              2008                  [@R22]
  South Korea   Clinical characteristics                                                                                                                                                                                         461            Cross-sectional study              2015                  [@R23]
  South Korea   Clinical characteristics                                                                                                                                                                                         364            Prospective cohort study           2018                  [@R24]
  Taipei        Incidence of cardiovascular complications in patients with ADPKD compared with general population                                                                                                                2062           National database study            2017                  [@R25]
  Turkey        Clinical characteristics                                                                                                                                                                                         1139           Cross-sectional study              2011                  [@R26]
  Turkey        Clinical characteristics and predictor of renal progression                                                                                                                                                      323            Retrospective study                2013                  [@R27]

ADPKD, autosomal dominant polycystic kidney disease.

The aim of this multinational, multicentre, retrospective cohort study was to determine the clinical characteristics of rapidly progressing patients with ADPKD in the Asia-Pacific region using the current recommendation for identification of rapid progression.[@R5] Data on clinical characteristics, complications and disease course of patients with ADPKD in the Asia-Pacific region will be collected. An exploratory goal of this project is to determine whether there are racial differences in disease progression, contributing to a baseline knowledge to inform future studies on this group of patients.

Methods and analysis {#s2}
====================

Study design {#s2-1}
------------

The RAPID-ADPKD (*R*etrospective epidemiological study of *A*sia-*P*acific patients with rap*I*d *D*isease progression of *A*utosomal *D*ominant *P*olycystic *K*idney *D*isease) study is a multinational, retrospective observational cohort study designed to determine the prevalence of patients with ADPKD with rapid progression in the Asia-Pacific region based on changes in renal function, kidney size and progression to ESRD.

Organisation {#s2-2}
------------

This study will enrol patients with ADPKD who have visited one of the six hospitals from the six countries in the Asia-Pacific region: (1) Westmead Hospital, Westmead, Australia; (2) Changzheng Hospital, Shanghai, China; (3) Queen Mary Hospital, Hong Kong; (4) Seoul National University Hospital, South Korea; (5) National Taiwan University Hospital, Taipei, Taiwan; and (6) Istanbul Bilim University, Turkey.

Study population {#s2-3}
----------------

After retrospectively reviewing patients' data from each hospital, we will enrol adult patients with ADPKD aged ≥18 years old (≥19 years old for patients in Taiwan due to the different age criteria for adults in this country) with an estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m^2^ at the index date of the study. To ensure sufficient follow-up duration for each patient in both the retrospective analysis and in the possible next step of the study, we planned to enrol patients with ADPKD with relatively preserved renal function. The index date is the first available date of reviewed medical records between January 2010 and the enrolment period. Enrolled patients are patients diagnosed with ADPKD according to the unified ultrasound criteria for patients with a family history of ADPKD[@R31]: at least two (unilateral or bilateral) renal cysts at age 18--29, at least two cysts in each kidney at age 30--59 years, and more than four bilateral renal cysts at age ≥60 years. For patients without a family history of ADPKD, those with clinical diagnosis of ADPKD based on typical radiological findings and/or clinical evaluation will also be included. Patients should have at least two clinical visits with eGFR measurements between 1 January 2010 and at the time at enrolment. In addition, at the time of enrolment, patients should have followed up with the centre during the last 24 months. Patients should also have at least 2 years of clinical follow-up records from the index date ([figure 1](#F1){ref-type="fig"}). Patients with severe heart failure (with symptoms of New York Heart Association class 3 and 4), severe liver disease (Child-Pugh class B or C), chronic inflammatory disease, diabetic nephropathy, vascular disease and/or other comorbidities that can affect renal function will be excluded based on the clinician's judgement. Patients with active cancer who underwent chemotherapy during the observation period will also be excluded from the study. Any medical or surgical conditions that can affect renal function or kidney volume will be excluded as well. The expected sample size of this multinational, retrospective observational cohort is more than 1000 patients.

![Planned structure and data collection in RAPID-ADPKD study. CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; ESRD, end-stage renal disease; PKD, polycystic kidney disease; PRO-PKD, Predicting Renal Outcomes in Autosomal Dominant Polycystic Kidney Disease; RAPID-ADPKD, *R*etrospective epidemiological study of *A*sia-*P*acific patients with rap*I*d *D*isease progression of *A*utosomal *D*ominant *P*olycystic *K*idney *D*isease.](bmjopen-2019-034103f01){#F1}

Data collection {#s2-4}
---------------

Demographic information at index date, such as gender, date of birth, race, height and body weight, will be collected. Comorbid conditions including diabetes mellitus, dyslipidaemia, hypertension, valvular heart disease, pericardial effusion or left ventricular hypertrophy based on echocardiography, chronic pulmonary disease, coronary artery disease, cerebrovascular disease, and cancer will be investigated. In addition, blood pressure, smoking history and CKD stage based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR at index date will also be collected. CKD-EPI eGFR will be calculated using the following formula: eGFR = 141 × min (Scr × 0.0113/k, 1)^α^ × max (Scr × 0.0113/k, 1)^−1.209^ × 0.993^Age^ × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, k is 0.7 for women and 0.9 for men, ^α^ is −0.329 for women and −0.411 for men, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1.[@R32] Family history of ESRD, medications (antihypertensive agents including calcium channel blocker, ACE, angiotensin receptor blocker and beta blocker, uric acid-lowering agent, antidiabetic agents including metformin, dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium glucose cotransporter (SGLT-2) inhibitor, lipid-lowering agents including statins, and others) and laboratory results (serum albumin, total bilirubin, cholesterol, high-density lipid, low-density lipid, triglyceride, alanine aminotransferase (ALT), aspartate aminotransferase (AST), sodium, potassium, chloride, blood urea nitrogen, glucose and uric acid) will also be collected. At the index date and during the follow-up visits, serum creatinine, urine protein:creatinine ratio, height-adjusted total kidney volume (htTKV) from radiological findings on MRI, CT or ultrasound sonography, renal and extrarenal ADPKD-related complications (cyst infection, events or imaging-diagnosed haemorrhagic cysts, proteinuria, kidney stone, gross haematuria, microscopic haematuria, chronic pain, upper urinary tract infection, hypertension, hyperuricaemia, hernia, liver cysts, intracranial aneurysms, subarachnoid haemorrhage, abdominal aorta aneurysms and infertility), and procedures (nephrectomy, sclerotherapy, embolisation, renal replacement therapy, hepatectomy, liver transplantation, fenestration and intervention for intracranial aneurysm) will be investigated.

From the reviewed data, the Predicting Renal Outcomes in autosomal dominant Polycystic Kidney Disease (PRO-PKD) score and event information including ESRD, major cardiovascular events (myocardial infarction, hospitalisation for unstable angina, transient ischaemic attack and stroke, heart failure requiring hospitalisation and peripheral artery revascularisation procedure) and death will be collected using an electronic case report form. PRO-PKD score will be calculated based on the following: a score of 1 for men, a score of 2 for hypertension before 35 years of age, a score of 2 for having first urological event such as macroscopic haematuria, flank pain or cyst infection before 35 years of age, a score of 2 for non-truncating *PKD1* mutation, and a score 4 for truncating *PKD1* mutation based on genetic testing results[@R28] ([figure 1](#F1){ref-type="fig"}).

Serum creatinine measurement and eGFR calculation {#s2-5}
-------------------------------------------------

To identify patients with rapid disease progression, standardising creatinine measurement is important. However, this is a multinational retrospective study, and serum creatinine measurement methods inevitably differ from different centres and dates. To reduce error in the interpretation of eGFR due to various creatinine measurement methods used, in addition to collecting the serum creatinine value we will also collect data on creatinine measurement methods such as the Jaffe method (calibrated with isotopic dilution mass spectrometry), enzymatic method, alkaline picrate kinetic, alkaline picrate rate-blanked method with compensation and alkaline picrate rate-blanked method without compensation, as supporting data during the analysis. In the calculation of eGFR, if the creatinine measurement was not calibrated with isotopic dilution mass spectrometry, eGFR will be calculated using the 5% reduced value of the recorded serum creatinine.[@R33] All eGFR values will be calculated based on the CKD-EPI equation.[@R32]

Total kidney volume calculation {#s2-6}
-------------------------------

To collect the maximum amount of htTKV data, we will gather data from renal MRI, CT or ultrasound images undertaken during the follow-up. The imaging dates and methods will be collected. If the htTKV has already been measured using imaging, the value and the measurement methods for total kidney volume (TKV) (ellipsoid, stereological measurement or other) will be collected. If there is no measurement done, htTKV will be calculated using the ellipsoid methods.[@R34] For the analysis, htTKV calculated by ellipsoid methods would be used mainly to define rapid progression. However, if other methods for calculating htTKV, such as stereological or planimetry, are used on the same patient, the progression will also be determined using the values derived from these methods. In both cross-sectional and longitudinal analyses, htTKV data will be analysed and presented according to TKV measurement methods separately and combined.

Follow-up {#s2-7}
---------

Follow-up duration will be defined from the index date until the enrolled date. Date of events such as ESRD, major cardiovascular events and death during the follow-up will be collected and used in the analysis ([figure 1](#F1){ref-type="fig"}).

Outcome variables {#s2-8}
-----------------

The cohort will include patients with more than two records of eGFR and ≥24 months of follow-up. The primary outcome of the study is the rate of decline in kidney function in the Asia-Pacific ADPKD population. Changes in eGFR slope during the follow-up will be calculated using generalised linear mixed model and compared between patients with rapid progression and those with slow progression. Rapid progression will be defined when any of the following criteria are met, based on European Renal Association -- European Dialysis and Transplant Association (ERA-EDTA) recommendations[@R5]: (1) an annual eGFR decline ≥5 mL/min/1.73 m^2^ within 1 year and/or ≥2.5 mL/min/1.73 m^2^ per year over a period of 5 years; (2) an increase in htTKV ≥5% per year measured from ≥3 radiological images; (3) Mayo classification 1C, 1D or 1E, or kidney length of \>16.5 cm on ultrasonography; and (4) *PKD1* truncated mutation with early symptoms (PRO-PKD score \>6). The remainder of the patients will be classified as slow progressors. The secondary outcome of the study is differences in other clinical characteristics including TKV changes, complication rate, age of complication presentation and treatment aspects between patients with rapid progression and those with slow progression. In addition, a subgroup analysis according to age group and ethnicity will be conducted as secondary outcome measures.

Data collection, monitoring and management {#s2-9}
------------------------------------------

The entire data collection and monitoring will be managed by a contract research organisation (CRO). The person designated to input data at each centre will be trained by the clinical research associate (CRA) before enrolment of the first patients to ensure uniformity of data at different centres and to minimise data input errors. Patients' eligibility for the study and final inclusion will be decided by the clinician at each centre according to the inclusion and exclusion criteria. All retrospective data will be collected using an electronic case report form. The CRA will visit the centre during the period of data collection and input and will regularly communicate with the person at the centre to determine data input errors and manage possible issues beforehand. Once the data from each centre have been recorded in the case report form, internal monitoring will be conducted. Once the data from all centres have been recorded in the case report form, external monitoring will be performed by the CRO. Missing data on continuous variables will be categorised as 'missing'. Data from 600 patients have been collected as of 30 May 2019.

Statistical methods {#s2-10}
-------------------

Once all data have been recorded and monitored, statistical analysis will be conducted on both the total study population and each country's population. If a certain variable cannot be collected at a specific centre, the analysis of that variable will be conducted after excluding the missing values. The analysis will be conducted following the guidelines of the International Committee on Harmonisation E9: Statistical Principles for Clinical Trials.[@R35]

For the primary analysis, all clinical variables will be analysed according to two categories: the rapid progressor and the slow progressor. Additional analysis will be conducted according to CKD stage, age group (≤30, 31--40, 41--50 and ≥51 years old), country and race. For the statistical analysis of categorical variables, χ^2^ test will be used. For continuous variables, Student's t-test and analysis of variance will be conducted. To compare changes in eGFR and htTKV, the generalised linear mixed model will be used to adjust the baseline difference between the individuals. Event data will be analysed using Cox proportional hazard model. P\<0.05 will be interpreted as statistically significant. For multiple comparisons, the Holm-Bonferroni method will be used.

Clinical significance of the study {#s2-11}
----------------------------------

This RAPID-ADPKD study has been designed to present the clinical data profile of the ADPKD population in the Asia-Pacific region. This study will include patients with ADPKD from six different countries in the Asia-Pacific region---Australia, China, Hong Kong, South Korea, Taiwan and Turkey---and hence will have heterogeneous ADPKD population consisting of different races, such as Han Chinese, Korean, Turks, Kurds, Taiwanese aborigines, Caucasians and so on. Using data from six Asia-Pacific countries, we aim to identify the risk factors for the rapid progression of disease in patients with ADPKD in the Asia-Pacific. To address the renal progression of the study population, htTKV and eGFR of the enrolled patients will be retrospectively reviewed and collected.

We also expect to analyse the current status of patients with ADPKD in the Asia-Pacific region, such as the pattern of extrarenal complication, diagnosis, treatment and medical resource utilisation. Patients with ADPKD are known to have a higher risk for hypertension and cardiovascular events compared with the general population.[@R36] However, in the CKD population, there have been studies reporting that hypertension is better controlled and the incidence of cardiovascular events lower in the Asian population compared with the Western CKD population.[@R39] Whether the incidence of hypertension and cardiovascular event is relatively low in Asian patients with ADPKD compared with the Western population, as in other patients with CKD, is unknown. In addition, the Asian population has relatively smaller body mass compared with the Western population, and there might be a higher incidence of complications due to severe polycystic liver disease and organomegaly in Asian patients with ADPKD. Using the retrospective data from RAPID-ADPKD study, we are planning to analyse the incidence of extrarenal complications in the Asian ADPKD population. Moreover, medical resource utilisation is influenced by the medical system and the government's reimbursement system. Therefore, the diagnostic pattern and assessment methods of disease progression during the follow-up would be different in the Asia-Pacific countries compared with Western countries. For example, MRI is a gold standard tool for TKV measurement, but it is not reimbursed by the medical system in most Asia-Pacific countries; ultrasonography or CT is instead preferred in clinical settings. The results from the current study would provide much information about the current assessment protocol in Asian ADPKD population, which would be valuable in planning for future clinical studies in Asian patients with ADPKD.

In this study, data on ethnicity will also be collected to analyse racial differences in Asian ADPKD population. Only a couple of studies have evaluated ADPKD progression in different races. Freedman *et al* [@R42] reported that African--American patients with ADPKD showed faster renal progression compared with Caucasian patients with ADPKD in the USA.[@R43] With regard to the Asian population, Muto *et al* [@R20] reported from the Japanese subset study of Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 4:3 trial, that the response to tolvaptan was different in terms of the annual rate of TKV growth in the Japanese population compared with that of the total population. Further studies on racial differences would give us an indepth understanding of the disease pathophysiology and would help identify rapid progressors. Therefore, the effect of race on clinical manifestation and renal progression, which would be analysed in the RAPID-ADPKD study, would be another valuable finding.

It is known that the serum antidiuretic hormone vasopressin level is elevated in dehydrated patients and this is related to the growth of cysts in ADPKD.[@R44] Based on this, sufficient water intake, as well as vasopressin V2 receptor antagonist, has been practised to slow renal progression in patients with ADPKD.[@R4] While the beneficial effect of increased water intake has been supported by animal studies, there are not enough human studies to support this recommendation. A randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to ADPKD (PREVENT-ADPKD), is currently under way.[@R45] In the RAPID-ADPKD study, by collecting and analysing data on spot urine specific gravity as a marker of water intake in a relatively large number of patients, we expect to provide baseline data on the effect of water intake in patients with ADPKD.

Limitations {#s2-12}
-----------

Since this is a retrospective, observational cohort study from six different countries, we expect several limitations will exist. As mentioned earlier, eGFR and htTKV, the two major indicators of disease progression in ADPKD, cannot be measured or interpreted using a unified method. Additionally, follow-up intervals or htTKV measurements will be different among different participating countries. In addition, there might be an insufficient number of patients who can provide genetic data, which is a known important prognostic marker of renal progression in ADPKD. A minimum follow-up data of 2 years would not be sufficient to identify patients with rapid progression, as suggested in the ERA-EDTA guideline. Also, a population with relatively preserved renal function would not show enough renal changes during a minimum follow-up of 2 years. Moreover, we could not evaluate renal function using cystatin C or inulin clearance, which would be more appropriate methods especially for patients with sarcopaenia with severe polycystic liver disease. Nevertheless, we believe that our analysis using eGFR and htTKV would provide valuable findings since we will collect data from actual clinical practice and from a large number of patients across different countries. Despite some limitations due to the nature of a multinational, retrospective observational study, we expect that our results will provide valuable knowledge on the clinical characteristics and the rapid progression of Asian patients with ADPKD, and for the first time will provide basic information on current practice in the Asia-Pacific region. Based on the findings of this study, we hope other well-organised multinational prospective studies are designed and conducted to identify the clinical characteristics and unique risk factors of the Asian ADPKD population.

Ethics and dissemination {#s2-13}
------------------------

This study is a retrospective, observational cohort study, and there are no interventions provided to the study subjects. Therefore, this study presents no more than minimal risk of harm to the study subjects. Also, all institutional review boards approved the consent waiver. All data collected for the study will be managed according to a non-disclosure agreement and privacy legislation. Data will be stored for at least 5 years after completion of enrolment but can be deleted according to each country's privacy regulations. The results will be presented in conferences and published in a journal, presenting data on the clinical characteristics, risk factors for disease progression and patterns of complications of ADPKD in Asian populations.

Patient and public involvement {#s2-14}
------------------------------

In this study, patients or the public were not involved in the design, conduct, reporting or dissemination of research.
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